Search
BridgeBio Pharma Inc
BBIOAdd to Watchlist
65.350USD
+0.310+0.48%
Close 10-09 16:00（ET）
12.80BMarket Cap
LossP/E TTM
BridgeBio Pharma Inc (BBIO) Stock Price Target & Forecast
Analyst Rating
Based on 23 analysts giving stock ratings to BridgeBio Pharma Inc in the past month.
Buy
4 Strong Buy
17 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
109.012USD+63.93%
BBIO Analyst Recommendation Trends
In the current month, BBIO has received 17 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. BBIO average Analyst price target in the last month is 109.012.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
4
4
6
6
7
7
6
6
17
17
17
16
17
16
16
16
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23
23
25
24
24
23
22
22
BBIO Analyst Rating for Peer Comparison
Updated: Oct 10, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
8
16
12
1
0
37
Amgen Inc
AMGN
4
12
18
2
1
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
AbbVie Inc
ABBV
8
19
6
0
0
33
Merck & Co Inc
MRK
7
16
8
0
0
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
2
0
31
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, BBIO EPS is projected to reach -0.641 in FY2026Q3, following reported EPS of -0.777 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.74
-0.68
-0.58
-0.64
-0.54
Actual
-1.00
-0.84
-0.78
--
--
Surprise
-34.25%
-24.11%
-33.25%
--
--
FAQs
What is BridgeBio Pharma Inc's expected revenue for the next quarter?
BridgeBio Pharma Inc's expected revenue is 270.24M.
What is BridgeBio Pharma Inc's price target?
Analysts forecast that BridgeBio Pharma Inc's price target is USD 109.01, with the highest forecast at USD 156.00 and the lowest forecast at USD 80.00.
How have BridgeBio Pharma IncBBIO's recent earnings per share performed?
The market expectation was USD -0.78, while BridgeBio Pharma IncBBIO's earnings per share (EPS) for the previous quarter was USD -0.84. EPS for the next quarter is expected at USD -0.64.
What is the analyst rating for BridgeBio Pharma Inc?
Based on the ratings of BridgeBio Pharma Inc's stock from 23 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.